>
"I've Always Gotten Along with President Putin" | Trump's TED Talk on War and Frie
The court is calling: How pickleball is rewiring brains, one volley at a time
SpaceX aims to launch Starship Flight 10 test flight on Aug. 24
What is Peter Thiel's Role In The Technocratic Takeover Of Washington?
Chinese Scientists Produce 'Impossible' Steel to Line Nuclear Fusion Reactors in Major Break
1,000 miles: EV range world record demolished ... by a pickup truck
Fermented Stevia Extract Kills Pancreatic Cancer Cells In Lab Tests
3D printing set to slash nuclear plant build times & costs
You can design the wheels for NASA's next moon vehicle with the 'Rock and Roll Challenge
'Robot skin' beats human reflexes, transforms grip with fabric-powered touch
World's first nuclear fusion plant being built in US to power Microsoft data centers
The mitochondria are more than just the "powerhouse of the cell" – they initiate immune...
Historic Aviation Engine Advance to Unlock Hypersonic Mach 10 Planes
OpenAI CEO Sam Altman Pitches Eyeball-Scanning World ID to Bankers
A groundbreaking study published in the Journal of Biomolecular Structure and Dynamics suggests just that — revealing how a natural compound found in licorice root might be a powerful weapon against breast cancer.
The sweet science behind glycyrrhizin
Glycyrrhizin, the active ingredient in licorice root responsible for its sweetness, has been used for centuries in traditional medicine to treat everything from sore throats to digestive issues. But now, researchers are uncovering its potential as a natural cancer-fighting agent. (Related: Licorice contains powerful cancer-killing phytochemicals.)
Using advanced computer modeling and bioinformatics — a subdiscipline of biology and computer science that uses software tools to analyze and interpret biological data — Iranian researchers mapped out exactly how this compound interacts with breast cancer cells, and the results are promising.
The study dug deep into the molecular pathways glycyrrhizin takes to combat cancer. Specifically, it focused on the breast cancer genes glycyrrhizin targets and how the compound interacts with the genes' protein products.
Of the 10 breast cancer-related genes the researchers looked at, they found that glycyrrhizin showed the highest binding affinity to three genes, namely, POLK, TBXAS1 and ADRA1A. These genes are active in three types of breast cancer: breast carcinoma, malignant neoplasm of the breast and triple-negative breast neoplasms.
The researchers reported that the protein products of these genes "had an association with [breast cancer] at several stages of tumor growth." By binding to and influencing the activities of these targets, glycyrrhizin is able to influence and control breast cancer growth and survival efficiently.
Molecular dynamics simulation also revealed that of the three interactions mapped out by the study, the destructive pathways triggered by glycyrrhizin's binding to ADRA1A had the highest likelihood of occurring.